{"id":"priming-dose-of-ribavirin-given","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Hemolytic anemia"},{"rate":null,"effect":"Teratogenicity/embryocidal effects"},{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Headache"},{"rate":"10-20","effect":"Dyspnea"},{"rate":"15-25","effect":"Nausea"},{"rate":"10-15","effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ribavirin is converted intracellularly to its active triphosphate form, which inhibits inosine monophosphate dehydrogenase (IMPDH), depleting guanosine nucleotides essential for viral RNA synthesis. It also directly inhibits viral RNA-dependent RNA polymerase and can cause mutagenesis of viral genomes. The 'priming' dose refers to an initial loading dose used to rapidly achieve therapeutic concentrations.","oneSentence":"Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with guanosine triphosphate metabolism and viral polymerase function.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:44:11.279Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C (in combination with interferon or direct-acting antivirals)"},{"name":"Severe respiratory syncytial virus (RSV) infection"},{"name":"Hemorrhagic fever with renal syndrome"}]},"trialDetails":[{"nctId":"NCT01226771","phase":"PHASE3","title":"Ribavirin Loading Dose or Priming and Concentration Targeting for HCV Genotype 1","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2010-09","conditions":"Hepatitis C","enrollment":105}],"_emaApprovals":[],"_faersSignals":[{"count":511,"reaction":"DRUG INEFFECTIVE"},{"count":451,"reaction":"MACULAR DEGENERATION"},{"count":449,"reaction":"OFF LABEL USE"},{"count":422,"reaction":"PYREXIA"},{"count":306,"reaction":"NAUSEA"},{"count":288,"reaction":"PAIN"},{"count":272,"reaction":"MALAISE"},{"count":268,"reaction":"CYTOKINE RELEASE SYNDROME"},{"count":235,"reaction":"WEIGHT DECREASED"},{"count":228,"reaction":"CONSTIPATION"}],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"\"Priming\" dose of ribavirin given","genericName":"\"Priming\" dose of ribavirin given","companyName":"Göteborg University","companyId":"g-teborg-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with guanosine triphosphate metabolism and viral polymerase function. Used for Chronic hepatitis C (in combination with interferon or direct-acting antivirals), Severe respiratory syncytial virus (RSV) infection, Hemorrhagic fever with renal syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}